{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:17:35Z","timestamp":1778249855300,"version":"3.51.4"},"reference-count":20,"publisher":"Endocrinology Research Centre","issue":"4","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p><jats:bold>RATIONALE<\/jats:bold>: Insufficient world\u2013wide clinical experience in radioiodine therapy (RIT) for Graves\u2019 disease (GD) in children and adolescents, and limited knowledge of the predictors of RIT efficacy.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold>: Analysis and identification of the most significant predictors of the efficacy of RIT in children and adolescents with Graves\u2019 disease.<\/jats:p><jats:p><jats:bold>MATERIALS AND METHODS<\/jats:bold>: A total of 55 patients (48 females and 7 males) aged from 8 to 18 years receiving primary RIT for GD were enrolled. RIT planning was based on the dosimetric method. Analyzed parameters included gender, age, ultrasound thyroid volume before and 6 months after treatment, the presence of endocrine ophthalmopathy, duration of antithyroid drug (ATD) therapy, relapse of thyrotoxicosis after ATD dose reduction, blood fT3, fT4 and TSH levels initially and at 1, 3, 6 months after treatment, TSH receptor Ab initially and at 3 and 6 months after treatment, thyroid\u00a0<jats:sup>99m<\/jats:sup>Tc\u2013pertechnetate uptake at 10\u201320 minutes (%), maximum thyroid <jats:sup>131<\/jats:sup>I uptake (%), specific\u00a0<jats:sup>131<\/jats:sup>I uptake (MBq\/g) and therapeutic\u00a0<jats:sup>131<\/jats:sup>I activity (MBq). Fisher exact test, non\u2013parametric Mann\u2013Whitney test, Wilcoxon signed\u2013rank test, logistic regression modelling, ROC\u2013analysis, proportional hazard model (the Cox regression), the Kaplan\u2013Meier method and log\u2013rank test were used for statistical analysis as appropriate.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>: Six months after RIT, hypothyroidism was achieved in 45 (81.8%), euthyroid state \u2013 in 2 (3.6%), and in 8 (14.6%) patients thyrotoxicosis persisted. On univariate statistical analysis, the smaller thyroid volume, higher fT4 and lower TSH receptor Ab levels, lower <jats:sup>99m<\/jats:sup>Tc\u2013pertechnetate uptake and higher specific <jats:sup>131<\/jats:sup>I uptake were associated with hypothyroidism. On multivariate logistic regression analysis, the older patient\u2019s age (p=0.011), smaller thyroid volume (p=0.003) and higher fT4 (p=0.024) were independent predictors of RIT efficacy. Thyroid volume was also the only variable associated with achievement of hypothyroidism in time after RIT (p=0.011).<\/jats:p><jats:p><jats:bold>CONCLUSION<\/jats:bold>: The efficacy of dosimetry\u2013based RIT in children and adolescents with GD 6 months after treatment was 81.2%. Older patients\u2019 age, smaller thyroid volume and higher fT4 level were independent predictors of therapy success. Smaller thyroid volume was also a predictor of the favorable time\u2013related outcome. Statistical models obtained in this work may be used to prospectively estimate the chance of efficient RIT for GD in pediatric patients.<\/jats:p>","DOI":"10.14341\/probl12390","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T11:05:04Z","timestamp":1607425504000},"page":"68-76","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":5,"title":["Predictors of the efficacy of radioiodine therapy of Graves\u2019 disease in children and adolescents"],"prefix":"10.14341","volume":"66","author":[{"given":"Pavel O.","family":"Rumyantsev","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir A.","family":"Saenko","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3071-4314","authenticated-orcid":true,"given":"Dali S.","family":"Dzeytova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey A.","family":"Trukhin","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina S.","family":"Sheremeta","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin Yu.","family":"Slashchuk","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail V.","family":"Degtyarev","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey S.","family":"Serzhenko","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina S.","family":"Yasuchenia","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana M.","family":"Zakharova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaroslav I.","family":"Sirota","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kraiem Z, Newfield RS. Graves\u2019 disease in childhood. J Pediatr Endocrinol Metab. 2001;14(3):229\u2013243. doi: 10.1515\/jpem.2001.14.3.229.","DOI":"10.1515\/JPEM.2001.14.3.229"},{"key":"ref2","unstructured":"Muratova ST, Ismailov SI. Mental characteristics of teenagers with Graves\u2019 disease in Uzbekistan. European science review (Vienna). 2015;7-8:77\u201380."},{"key":"ref3","unstructured":"Chernyshova VS, Stol\u2019nikova TG, Evtukhova OV, Kulakova EN. Osobennosti klinicheskoy kartiny diffuznogo toksicheskogo zoba u detey Voronezhskoy oblasti. Meditsina: teoriya i praktika. 2019;4(S):601. (In Russ.)."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Glaser NS, Styne DM. Organization of Pediatric Endocrinologists of Northern California Collaborative Graves\u2019 Disease Study G. Predicting the likelihood of remission in children with Graves\u2019 disease: a prospective, multicenter study. Pediatrics. 2008;121(3):481\u2013488. doi: 10.1542\/peds.2007-1535.","DOI":"10.1542\/peds.2007-1535"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Takaya K, Kimura N, Hiyoshi T. Antithyroid arthritis syndrome: a case report and review of the literature. Intern Med. 2016:55(24):3627\u20133633. doi: 10.2169\/internalmedicine.55.7379.","DOI":"10.2169\/internalmedicine.55.7379"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Nikitopoulou E, Gazi S. Antithyroid drug induced syndrome that lies in between ANCA vasculitis and lupus-like syndrome in a 40-year-old female with Graves\u2019 disease under methimazole therapy: A Case report. Mediterr J Rheumatol. 2018:19;29(1):52\u201354. doi: 10.31138\/mjr.29.1.52.","DOI":"10.31138\/mjr.29.1.52"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ismailov SI, Khayitboeva KK. Problems of diagnostics and treatment of diffuse \u2212 toxic goiter (Graves\u2019 disease). Vestnik of Saint Petersburg University. Medicine. 2019;14(2):98\u2013104. doi: 10.21638\/spbu11.2019.202.","DOI":"10.21638\/spbu11.2019.202"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Rumiantsev PO, Sheremeta MS, Kiyaev AV, et al. Efficacy and safety of radioiodine treatment of Graves\u2019 disease in children and adolescents. Clinical and experimental thyroidology. 2017;13(1):6\u201311. (In Russ.). doi: 10.14341\/ket201716\u201311.","DOI":"10.14341\/ket201716-11"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Bezlepkina OB. Federal clinical guidelines for the diagnosis and treatment of Graves\u2019 disease in children. Problems of Endocrinology. 2014;60(3):59\u201368 (In Russ.). doi: 10.14341\/probl201460359-68.","DOI":"10.14341\/probl201460359-68"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kahaly GJ, Bartalena L, Heged\u00fcs L, et al. 2018 European thyroid association guideline for the management of graves\u2019 hyperthyroidism. Eur Thyroid J. 2018;7(4):167\u2013186. doi: 10.1159\/000490384.","DOI":"10.1159\/000490384"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rumiantsev PO, Korenev SV. The history of radioiodine therapy beginnings. Clinical and experimental thyroidology. 2015;11(4):51\u201355. (In Russ.). doi: 10.14341\/ket2015451-55.","DOI":"10.14341\/ket2015451-55"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Rumiantsev PO, Kiyaev AV, Sheremeta MS, Chikulaeva OA. Radioiodine therapy of thyrotoxicosis in children and adolescents. Indications, efficacy and safety. Literature review. Endocrine surgery. 2016;10(4):6\u201312. (In Russ.). doi: 10.14341\/serg201646-12.","DOI":"10.14341\/serg201646-12"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Gambhir S, Barai S. Radioiodine for treatment of graves\u2019 disease in pediatric population: an ideal treatment. World J Endocr Surg. 2010;2(2):77\u201380. doi: 10.5005\/jp-journals-10002-1026.","DOI":"10.5005\/jp-journals-10002-1026"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343\u20131421. doi: 10.1089\/thy.2016.0229.","DOI":"10.1089\/thy.2016.0229"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Stokkel MP, Handkiewicz Junak D, Lassmann M, et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218\u20132228. doi: 10.1007\/s00259-010-1536-8.","DOI":"10.1007\/s00259-010-1536-8"},{"key":"ref16","unstructured":"Pandey M, Jain A. ROC Curve: Making way for correct diagnosis. SP11-PharmaSUG 2016 [Internet]. Available from: https:\/\/www.pharmasug.org\/proceedings\/2016\/SP\/PharmaSUG-2016-SP11.pdf."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111(4 Pt 1):745\u2013749. doi: 10.1542\/peds.111.4.745.","DOI":"10.1542\/peds.111.4.745"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Kaplowitz PB, Jiang J, Vaidyanathan P. Radioactive iodine therapy for pediatric Graves\u2019 disease: a single-center experience over a 10-year period. J Pediatr Endocrinol Metab. 2019;33(3):383\u2013389. doi: 10.1515\/jpem-2019-0316.","DOI":"10.1515\/jpem-2019-0316"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Namwongprom S, Unachak K, Dejkhamron P\u041c, et al. Radioactive iodine for thyrotoxicosis in childhood and adolescence: Treatment and outcomes. JCRPE J Clin Res Pediatr Endocrinol. 2013;5(2):95\u201397. doi: 10.4274\/Jcrpe.951.","DOI":"10.4274\/Jcrpe.951"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"McCormack S, Mitchell DM, Woo M, et al. Radioactive iodine for hyperthyroidism in children and adolescents: referral rate and response to treatment. Clin Endocrinol (Oxf ). 2009;71(6):884\u2013891. doi: 10.1111\/j.1365-2265.2009.03565.x.","DOI":"10.1111\/j.1365-2265.2009.03565.x"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/12390\/9822","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T11:06:10Z","timestamp":1607425570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/12390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,7]]}},"URL":"https:\/\/doi.org\/10.14341\/probl12390","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,7]]}}}